ACADIA Pharmaceuticals Inc(ACAD)stock report

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer’s disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Market Cap:6200M; Shares Outstanding:154.0M; Short Interest: 7.33%; Q3 2019(9/30/19): Cash 684M. Loss 42M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -1.94 17.80% -34.72%
2019.3.31 -0.6 -34.52% 69.07%
2019.6.30 -0.97 -3.23% -61.67%
2019.9.30 -1.19 17.43% -22.68%


Date Sales % last year % last quarter
2018.12.31 224M 79.19% 36.59%
2019.3.31 62.96M 28.83% -71.89%
2019.6.30 146M 37.98% 131.89%
2019.9.30 241M 46.59% 65.07%


Insider Transactions:

Institution Ownership:

Total institutions: 266,no change
Shares hold: 151000k shares. Reduced 3.02k
shares% hold: 98%,no change

Analyst Ratings:

2020.01.17:ACADIA (ACAD) Up More Than 100% in the Past Year: Here’s Why

Leave a Reply